BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer.

CONCLUSIONS: We provide evidence that BETi either alone or in combination with FGFR1 inhibitors or BH3 mimetics may be a useful therapeutic strategy for recurrent ILC patients.
PMID: 31409615 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 12, 2019 Category: Cancer & Oncology Authors: Walsh L, Haley KE, Moran B, Mooney B, Tarrant F, Madden SF, Di Grande A, Fan Y, Das S, Rueda OM, Dowling CM, Varešlija D, Chin SF, Linn SC, Young LS, Jirström K, Crown J, Bernards R, Caldas C, Gallagher WM, O'Connor DP, Ni Chonghaile T Tags: Clin Cancer Res Source Type: research